|
BOTHELL, Wash., Dec. 16 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM.OB) today announced that Richard M. Cohen has been
appointed to its Board of Directors. The addition of Mr. Cohen increases the
size of Helix BioMedixs Board to eight. Mr. Cohen will also serve on the
Companys audit committee.
Mr. Cohen, age 54, is the Managing Principal of Richard M. Cohen
Consultants, Inc. (RMCC), which was formed to enhance shareholder value for
public and private company clients. He has more than two decades of diverse
business experience, including serving as president and chief financial
officer of several RMCC clients. Prior to forming RMCC in 1995, Mr. Cohen was
President of General Media, Inc., a major international publishing and media
company.
Mr. Cohen has an M.B.A. from Stanford University, a B.S. cum laude from
the Wharton School of Business at the University of Pennsylvania and is a
C.P.A. He is currently on the board of directors of Dune Energy, a publicly
traded oil and gas exploration company, and Flaghouse Communications, a
privately held marketer of physical education equipment.
R. Stephen Beatty, President and Chief Executive Officer of Helix
BioMedix, commented, "We are very excited to have Richard Cohen join our
Board. His financial expertise, Wall Street background and significant
hands-on operating experience make Richard an excellent candidate. In
addition, his diverse industry experience, including five years in consumer
marketing with Revlon, will prove valuable as we move ahead with the
commercialization of our proprietary peptides on the consumer product side."
About Helix BioMedix
Helix BioMedix, Inc. is an early-stage biopharmaceutical company that has
a portfolio of issued patents that covers six distinct classes of peptides,
including over 1 million unique peptide sequences. The companys mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the companys website at
http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements involve risks
and uncertainties, including activities, events or developments that the
company expects, believes or anticipates will or may occur in the future. A
number of factors could cause actual results to differ from those indicated in
the forward-looking statements, including the companys ability to
successfully raise additional capital, enter into revenue generating license
agreements, continue its research and development efforts, including
pre-clinical and clinical studies, and general economic conditions. Additional
assumptions, risks and uncertainties are described in detail in our reports
and other filings with the Securities and Exchange Commission. Such filings
are available on our website or at http://www.sec.gov. Readers are cautioned that
such forward-looking statements are not guarantees of future performance and
that actual results or developments may differ materially from those set forth
in the forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Helix BioMedix, Inc.
David H. Kirske, 425-402-8400
dkirske@helixbiomedix.com
Investor Relations:
Cameron Associates
Paul G. Henning, 212-554-5462
paul@cameronassoc.com
|
|
